Rifaximin Improves Quality of Life in Hepatic Encephalopathy Across Domains
This systematic review consolidates fragmented quality-of-life data on rifaximin in cirrhosis-related hepatic encephalopathy, offering pharmacists a patient-centered lens beyond ammonia reduction and recurrence prevention.
📅 Journal publication: Jul 16, 2026·Last updated: Oct 7, 2026
rifaximinlactuloseL-ornithine L-aspartatenitazoxanidehepatic encephalopathycirrhosisquality of lifesystematic reviewpatient-reported outcomesCLDQSIPGastroenterology / Hepatology
Background Information
Rifaximin may enhance quality of life for cirrhosis patients with hepatic encephalopathy.
Hepatic encephalopathy (HE) adversely affects quality of life (QoL) in patients with cirrhosis, making effective treatment crucial. Rifaximin generally improved overall and specific QoL scores compared to placebo, with outcomes similar to lactulose and other treatments. Although rifaximin shows promise in improving QoL for HE patients, study variability and limited evidence necessitate further research for definitive conclusions. Rifaximin may enhance quality of life in hepatic encephalopathy but further studies are warranted for clearer evidence.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Sacco R, Corti A, Giacomelli L, Facciorusso A
Citation:Sacco R, Corti A, Giacomelli L, et al. Quality of Life in Patients with Hepatic Encephalopathy Treated with Rifaximin: A Systematic Review. Journal of clinical medicine. 2026;15(14). doi:10.3390/jcm15145600
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.